Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 23.5 AMA PRA Category 1 CreditsTM.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by educational grants from Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, and Lilly USA, LLC. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
The 13th Annual International Lung Cancer Congress®will provide physicians with practical information regarding the clinical implications of lung cancer screening, the latest clinical data impacting the treatment of lung cancer, and novel agents and strategies that are changing the future of lung cancer therapy. The importance of personalized therapy will be emphasized, followed by other current topics of interest. State-of-the-art treatment for non–small-cell lung cancer (NSCLC) by stage, SCLC, and mesothelioma will be discussed.
Didactic lectures and debates will be used to reinforce current standards and to present emerging clinical data.
Faculty will discuss practice-changing data in a case-based framework that will provide physicians with the necessary context to integrate the information into their practice to improve treatment selection and patient care.
Panel discussions, multidisciplinary Tumor Boards, and question-and-answer sessions will allow the faculty to share their personal experiences and opinions on specific clinical scenarios and ongoing controversies in the treatment of lung cancer.
Recurring session will highlight clinical research activity of Cooperative Groups in the United States, Europe, and Asia.
This conference will provide invaluable education to practicing physicians to increase their knowledge and improve their performance in managing patients with lung cancer. This educational program will provide medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, and oncology professionals with practical information regarding the clinical implications of lung cancer screening, the latest clinical data impacting the treatment of lung cancer, and novel agents and strategies that are changing the future of lung cancer therapy.
This educational activity is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in lung cancer may also participate.
Upon completion of the educational activities, participants should be able to:
Interpret the updated AJCC staging guidelines and identify the changes to the way you assess and treat your patients with NSCLC that may be needed in order to adopt these guidelines.
Refer to the AJCC Staging Guidelines relative to TNM classification when selecting your patients with NSCLC for surgery, radiation, and chemotherapy.
Use histologic and molecular data, tumor and patient characteristics, in order to individualize therapy choices for your patients with NSCLC.
Evaluate the clinical data presented about new agents in development for lung cancer and determine which of your patients may be appropriate candidates for clinical trial enrollment.
You must be logged in to PER to register for this meeting